Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Enhabit Inc. (EHAB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: EHAB (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $10.25
1 Year Target Price $10.25
| 1 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -61.51% | Avg. Invested days 24 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 484.09M USD | Price to earnings Ratio - | 1Y Target Price 10.25 |
Price to earnings Ratio - | 1Y Target Price 10.25 | ||
Volume (30-day avg) 5 | Beta 1.39 | 52 Weeks Range 6.85 - 10.90 | Updated Date 06/29/2025 |
52 Weeks Range 6.85 - 10.90 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.77 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -13.43% | Operating Margin (TTM) 6.12% |
Management Effectiveness
Return on Assets (TTM) 2.31% | Return on Equity (TTM) -21.36% |
Valuation
Trailing PE - | Forward PE 20.62 | Enterprise Value 988193706 | Price to Sales(TTM) 0.47 |
Enterprise Value 988193706 | Price to Sales(TTM) 0.47 | ||
Enterprise Value to Revenue 0.96 | Enterprise Value to EBITDA 14.43 | Shares Outstanding 50637400 | Shares Floating 38989798 |
Shares Outstanding 50637400 | Shares Floating 38989798 | ||
Percent Insiders 2.93 | Percent Institutions 101.29 |
Analyst Ratings
Rating 3 | Target Price 10.25 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Enhabit Inc.
Company Overview
History and Background
Enhabit, Inc. was spun off from Encompass Health in July 2022, focusing solely on home health and hospice services. It has expanded its service area through acquisitions and organic growth, building upon the established infrastructure of Encompass Health's home health division.
Core Business Areas
- Home Health: Provides a range of medical services to patients in their homes, including skilled nursing, rehabilitation therapies, and home health aides. This segment comprises the majority of Enhabit's revenue.
- Hospice: Offers palliative care and support services to patients with terminal illnesses and their families, including medical, emotional, and spiritual support.
Leadership and Structure
The leadership team consists of President and CEO Barbara A. Jacobsmeyer, CFO Crissy Carlisle and other executive leaders. The company operates with a geographically decentralized structure, with regional and local management teams overseeing individual branches and service areas.
Top Products and Market Share
Key Offerings
- Home Health Services: Skilled nursing, physical therapy, occupational therapy, speech therapy, and home health aides. It is difficult to ascertain the exact market share of each product offered within home health. Competitors: LHC Group (LHCG), Amedisys (AMED), Brookdale Senior Living (BKD) providing similar home-based health services
- Hospice Care: Pain management, symptom control, emotional and spiritual support for terminally ill patients and their families. Like Home Health Services, market share data is difficult to isolate by individual service. Competitors: LHC Group (LHCG), Amedisys (AMED), Compassus, Kindred at Home (acquired by Humana).
Market Dynamics
Industry Overview
The home health and hospice industry is experiencing growth driven by an aging population, increasing preference for in-home care, and technological advancements that enable remote monitoring and telehealth. Regulatory changes and reimbursement models also influence the industry's dynamics.
Positioning
Enhabit is a large player in the home health and hospice market, with a wide geographic footprint. Its competitive advantage lies in its scale, established brand, and experienced workforce. However, the industry is fragmented and competitive, with numerous regional and local providers.
Total Addressable Market (TAM)
The US home healthcare market is estimated to be over $120 billion and growing, while the US hospice market is estimated to be around $40 billion and also growing. Enhabit is positioned to capture a share of this expanding market through organic growth, acquisitions, and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Established brand and reputation
- Large geographic footprint
- Experienced workforce
- Strong relationships with referral sources
Weaknesses
- Reliance on government reimbursement
- Labor shortages
- Operational complexities due to decentralized structure
- Potential for regulatory scrutiny
Opportunities
- Acquisitions of smaller providers
- Expansion into new geographic markets
- Development of telehealth and remote monitoring capabilities
- Partnerships with hospitals and other healthcare providers
Threats
- Changes in government reimbursement policies
- Increased competition
- Rising labor costs
- Economic downturn affecting patient demand
Competitors and Market Share
Key Competitors
- LHCG
- AMED
- HRHC
Competitive Landscape
The home health and hospice industry is competitive. Enhabit competes on the basis of quality of care, service offerings, geographic coverage, and price.
Major Acquisitions
Reliant at Home
- Year: 2023
- Acquisition Price (USD millions): 51
- Strategic Rationale: Expansion of services in the Texas region to increase market share
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the spin-off. Evaluate post-spin-off performance and growth metrics.
Future Projections: Analyst projections typically forecast continued revenue growth driven by demographic trends and market expansion.
Recent Initiatives: Focusing on telehealth, improving the referral process, and optimizing existing resources.
Summary
Enhabit is a major player in the growing home health and hospice market, benefiting from its established brand and wide service area. Its reliance on government reimbursement and labor market challenges are key concerns. Strategic acquisitions and expansion of telehealth services present growth opportunities. Monitoring financial health post spin-off is crucial for assessing long-term performance. The company's AI-Based Fundamental Rating is average, factoring in its market position and operational challenges.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market data and estimates are subject to change. The AI-based rating is for informational purposes only and should not be considered a recommendation to buy or sell stock.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enhabit Inc.
Exchange NYSE | Headquaters Dallas, TX, United States | ||
IPO Launch date 2022-07-01 | President, CEO & Director Ms. Barbara Ann Jacobsmeyer B.S., M.A., P.T. | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 10600 | Website https://www.ehab.com |
Full time employees 10600 | Website https://www.ehab.com | ||
Enhabit, Inc. provides home health and hospice services in the United States. The company's home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. It also provides hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.